A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis
Active, not recruiting · Phase 2 · NCT06975722
Conditions: Ulcerative Colitis
At a glance
- Research payments reported, 2025
- $477,132
- U.S. investigators named
- 19
- Sites paid
- 16
- Planned or actual enrollment
- 105
About the trial
- Sponsor
- Sanofi
- Tested
- SAR442970 (drug), Placebo (drug)
- Dates
- Started 2025-07-07; completion 2029-10-17
- Results posted
- Not yet
This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Ulcerative Colitis. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Ulcerative Colitis. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.
From ClinicalTrials.gov, last updated 2026-11-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $477,132 in research payments for this study in 2025 (111 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Nathaniel S. Winstead, MD Gastroenterology · Fairhope, AL
- Naveen Gara, M.D. Gastroenterology · San Diego, CA
- Mahendra N. Patel, M.D. Gastroenterology · Simi Valley, CA
- Kumaravel Perumalsamy, M.D. Gastroenterology · Lancaster, CA
- Amar R. Deshpande, MD Gastroenterology · Miami, FL
- Michael D. Feldman, DO Family Medicine · Village Of Palmetto Bay, FL
- Vipin Gupta, MD Gastroenterology · Lighthouse Point, FL
- Muhammad A. Mohiuddin, M.D. Gastroenterology · Kissimmee, FL
- Kristian E. Sanchack, MD Family Medicine · Jacksonville, FL
- Alexander Veloso, MD Gastroenterology · Miami, FL
- Aasim M. Sheikh, MD Gastroenterology · Marietta, GA
- Steven F. Polyak, MD Gastroenterology · Iowa City, IA
- Jessica R. Allegretti, M.D. Gastroenterology · Boston, MA
- Allan G. Coates, DO Gastroenterology · Wyoming, MI
- Parakkal Deepak, MD Gastroenterology · Saint Louis, MO
- Millie D. Long, MD Internal Medicine · Chapel Hill, NC
- Aryel Nicoleau, MD Internal Medicine · Queens Village, NY
- Adnan Ahmad, D.O. Gastroenterology · Camp Hill, PA
- Tugrul Purnak, M.D. Gastroenterology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Gastroenterology and Liver Institute $58,929
- The Clinical Trials Network Llc $43,600
- Nursing Ce Trust Fund $41,863
- The University of Texas Health Scie Center at Houston $38,752
- Alliance Medical Research, Llc $38,640
- Washington University Division $33,126
- A One Clinical Network Llc $32,300
- University of Iowa Hospital & Clinics, IA $31,141
- Research Associates of South Florida, Llc $25,631
- Brigham and Women's Hospital, MA $23,694
- Gastroenterology Associates of West Michigan Plc West Michigan Clinical Research Center $23,079
- Tropical Clinical Trials $21,140
- Green Leaf Clinical Trials $16,353
- Gastrointestinal Specialists of Ga $13,350
- Clinical Trials Management Services, Llc $12,320
- Central Florida Gastro Research Llc $12,000
- $11,214
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.